Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Cummings, SR; San Martin, J; McClung, MR; Siris, ES; Eastell, R; Reid, IR; Delmas, P; Zoog, HB; Austin, M; Wang, A; Kutilek, S; Adami, S; Zanchetta, J; Libanati, C; Siddhanti, S; Christiansen, C; FREEDOM Trial.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009; 361(8): 756-765. Doi: 10.1056/NEJMoa0809493 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Study Group Members Med Uni Graz:: Fahrleitner-Pammer Astrid
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS: We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures. RESULTS: As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. CONCLUSIONS: Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)
Find related publications in this database (using NLM MeSH Indexing): Aged -; Aged, 80 and over -; Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use; Bone Density - drug effects; Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use; Bone Remodeling - drug effects; Female -; Fractures, Bone - epidemiology Fractures, Bone - prevention and control; Hip Fractures - epidemiology Hip Fractures - prevention and control; Humans -; Incidence -; Middle Aged -; Osteoporosis, Postmenopausal - drug therapy; RANK Ligand - adverse effects RANK Ligand - pharmacology RANK Ligand - therapeutic use; Risk -; Spinal Fractures - epidemiology Spinal Fractures - prevention and control